Cargando…

Landscape of DILI-related adverse drug reaction in China Mainland

Drug-induced liver injury (DILI) is a type of bizarre adverse drug reaction (ADR) damaging liver (L-ADR) which may lead to substantial hospitalizations and mortality. Due to the general low incidence, detection of L-ADR remains an unsolved public health challenge. Therefore, we used the data of 6.67...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiabo, Song, Haibo, Ge, Feilin, Xiong, Peng, Jing, Jing, He, Tingting, Guo, Yuming, Shi, Zhuo, Zhou, Chao, Han, Zixin, Han, Yanzhong, Niu, Ming, Bai, Zhaofang, Luo, Guangbin, Shen, Chuanyong, Xiao, Xiaohe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764066/
https://www.ncbi.nlm.nih.gov/pubmed/36561993
http://dx.doi.org/10.1016/j.apsb.2022.04.019
_version_ 1784853196579012608
author Wang, Jiabo
Song, Haibo
Ge, Feilin
Xiong, Peng
Jing, Jing
He, Tingting
Guo, Yuming
Shi, Zhuo
Zhou, Chao
Han, Zixin
Han, Yanzhong
Niu, Ming
Bai, Zhaofang
Luo, Guangbin
Shen, Chuanyong
Xiao, Xiaohe
author_facet Wang, Jiabo
Song, Haibo
Ge, Feilin
Xiong, Peng
Jing, Jing
He, Tingting
Guo, Yuming
Shi, Zhuo
Zhou, Chao
Han, Zixin
Han, Yanzhong
Niu, Ming
Bai, Zhaofang
Luo, Guangbin
Shen, Chuanyong
Xiao, Xiaohe
author_sort Wang, Jiabo
collection PubMed
description Drug-induced liver injury (DILI) is a type of bizarre adverse drug reaction (ADR) damaging liver (L-ADR) which may lead to substantial hospitalizations and mortality. Due to the general low incidence, detection of L-ADR remains an unsolved public health challenge. Therefore, we used the data of 6.673 million of ADR reports from January 1st, 2012 to December 31st, 2016 in China National ADR Monitoring System to establish a new database of L-ADR reports for future investigation. Results showed that totally 114,357 ADR reports were retrieved by keywords searching of liver-related injuries from the original heterogeneous system. By cleaning and standardizing the data fields by the dictionary of synonyms and English translation, we resulted 94,593 ADR records reported to liver injury and then created a new database ready for computer mining. The reporting status of L-ADR showed a persistent 1.62-fold change over the past five years. The national population-adjusted reporting numbers of L-ADR manifested an upward trend with age increasing and more evident in men. The annual reporting rate of L-ADR in age group over 80 years old strikingly exceeded the annual DILI incidence rate in general population, despite known underreporting situation in spontaneous ADR reporting system. The percentage of herbal and traditional medicines (H/TM) L-ADR reports in the whole number was 4.5%, while 80.60% of the H/TM reports were new findings. There was great geographical disparity of reported agents, i.e. more cardiovascular and antineoplastic agents were reported in higher socio-demographic index (SDI) regions and more antimicrobials, especially antitubercular agents, were reported in lower SDI regions. In conclusion, this study presented a large-scale, unbiased, unified, and computer-minable L-ADR database for further investigation. Age-, sex- and SDI-related risks of L-ADR incidence warrant to emphasize the precise pharmacovigilance policies within China or other regions in the world.
format Online
Article
Text
id pubmed-9764066
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97640662022-12-21 Landscape of DILI-related adverse drug reaction in China Mainland Wang, Jiabo Song, Haibo Ge, Feilin Xiong, Peng Jing, Jing He, Tingting Guo, Yuming Shi, Zhuo Zhou, Chao Han, Zixin Han, Yanzhong Niu, Ming Bai, Zhaofang Luo, Guangbin Shen, Chuanyong Xiao, Xiaohe Acta Pharm Sin B Original Article Drug-induced liver injury (DILI) is a type of bizarre adverse drug reaction (ADR) damaging liver (L-ADR) which may lead to substantial hospitalizations and mortality. Due to the general low incidence, detection of L-ADR remains an unsolved public health challenge. Therefore, we used the data of 6.673 million of ADR reports from January 1st, 2012 to December 31st, 2016 in China National ADR Monitoring System to establish a new database of L-ADR reports for future investigation. Results showed that totally 114,357 ADR reports were retrieved by keywords searching of liver-related injuries from the original heterogeneous system. By cleaning and standardizing the data fields by the dictionary of synonyms and English translation, we resulted 94,593 ADR records reported to liver injury and then created a new database ready for computer mining. The reporting status of L-ADR showed a persistent 1.62-fold change over the past five years. The national population-adjusted reporting numbers of L-ADR manifested an upward trend with age increasing and more evident in men. The annual reporting rate of L-ADR in age group over 80 years old strikingly exceeded the annual DILI incidence rate in general population, despite known underreporting situation in spontaneous ADR reporting system. The percentage of herbal and traditional medicines (H/TM) L-ADR reports in the whole number was 4.5%, while 80.60% of the H/TM reports were new findings. There was great geographical disparity of reported agents, i.e. more cardiovascular and antineoplastic agents were reported in higher socio-demographic index (SDI) regions and more antimicrobials, especially antitubercular agents, were reported in lower SDI regions. In conclusion, this study presented a large-scale, unbiased, unified, and computer-minable L-ADR database for further investigation. Age-, sex- and SDI-related risks of L-ADR incidence warrant to emphasize the precise pharmacovigilance policies within China or other regions in the world. Elsevier 2022-12 2022-05-06 /pmc/articles/PMC9764066/ /pubmed/36561993 http://dx.doi.org/10.1016/j.apsb.2022.04.019 Text en © 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Wang, Jiabo
Song, Haibo
Ge, Feilin
Xiong, Peng
Jing, Jing
He, Tingting
Guo, Yuming
Shi, Zhuo
Zhou, Chao
Han, Zixin
Han, Yanzhong
Niu, Ming
Bai, Zhaofang
Luo, Guangbin
Shen, Chuanyong
Xiao, Xiaohe
Landscape of DILI-related adverse drug reaction in China Mainland
title Landscape of DILI-related adverse drug reaction in China Mainland
title_full Landscape of DILI-related adverse drug reaction in China Mainland
title_fullStr Landscape of DILI-related adverse drug reaction in China Mainland
title_full_unstemmed Landscape of DILI-related adverse drug reaction in China Mainland
title_short Landscape of DILI-related adverse drug reaction in China Mainland
title_sort landscape of dili-related adverse drug reaction in china mainland
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764066/
https://www.ncbi.nlm.nih.gov/pubmed/36561993
http://dx.doi.org/10.1016/j.apsb.2022.04.019
work_keys_str_mv AT wangjiabo landscapeofdilirelatedadversedrugreactioninchinamainland
AT songhaibo landscapeofdilirelatedadversedrugreactioninchinamainland
AT gefeilin landscapeofdilirelatedadversedrugreactioninchinamainland
AT xiongpeng landscapeofdilirelatedadversedrugreactioninchinamainland
AT jingjing landscapeofdilirelatedadversedrugreactioninchinamainland
AT hetingting landscapeofdilirelatedadversedrugreactioninchinamainland
AT guoyuming landscapeofdilirelatedadversedrugreactioninchinamainland
AT shizhuo landscapeofdilirelatedadversedrugreactioninchinamainland
AT zhouchao landscapeofdilirelatedadversedrugreactioninchinamainland
AT hanzixin landscapeofdilirelatedadversedrugreactioninchinamainland
AT hanyanzhong landscapeofdilirelatedadversedrugreactioninchinamainland
AT niuming landscapeofdilirelatedadversedrugreactioninchinamainland
AT baizhaofang landscapeofdilirelatedadversedrugreactioninchinamainland
AT luoguangbin landscapeofdilirelatedadversedrugreactioninchinamainland
AT shenchuanyong landscapeofdilirelatedadversedrugreactioninchinamainland
AT xiaoxiaohe landscapeofdilirelatedadversedrugreactioninchinamainland